These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

56 related items for PubMed ID: 9766573

  • 1. Suppression of Erk activation and in vivo growth in esophageal cancer cells by the dominant negative Ras mutant, N116Y.
    Senmaru N, Shichinohe T, Takeuchi M, Miyamoto M, Sazawa A, Ogiso Y, Takahashi T, Okushiba S, Takimoto M, Kato H, Kuzumaki N.
    Int J Cancer; 1998 Oct 29; 78(3):366-71. PubMed ID: 9766573
    [Abstract] [Full Text] [Related]

  • 2. Adenovirus-mediated gene therapy for bladder cancer in an orthotopic model using a dominant negative H-ras mutant.
    Watanabe T, Shinohara N, Sazawa A, Takimoto M, Hashimoto A, Koyanagi T, Kuzumaki N.
    Int J Cancer; 2001 Jun 01; 92(5):712-7. PubMed ID: 11340577
    [Abstract] [Full Text] [Related]

  • 3. Suppression of pancreatic cancer by the dominant negative ras mutant, N116Y.
    Shichinohe T, Senmaru N, Furuuchi K, Ogiso Y, Ishikura H, Yoshiki T, Takahashi T, Kato H, Kuzumaki N.
    J Surg Res; 1996 Dec 01; 66(2):125-30. PubMed ID: 9024823
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Inhibition of ras-dependent transformation by using dominant negative ras mutant N116Y].
    Yokoyama T.
    Hokkaido Igaku Zasshi; 1995 May 01; 70(3):459-71. PubMed ID: 7590597
    [Abstract] [Full Text] [Related]

  • 6. Suppression of various human tumor cell lines by a dominant negative H-ras mutant.
    Ogiso Y, Sakai N, Watari H, Yokoyama T, Kuzumaki N.
    Gene Ther; 1994 Nov 01; 1(6):403-7. PubMed ID: 7584106
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Reciprocal activation between PLK1 and Stat3 contributes to survival and proliferation of esophageal cancer cells.
    Zhang Y, Du XL, Wang CJ, Lin DC, Ruan X, Feng YB, Huo YQ, Peng H, Cui JL, Zhang TT, Wang YQ, Zhang H, Zhan QM, Wang MR.
    Gastroenterology; 2012 Mar 01; 142(3):521-530.e3. PubMed ID: 22108192
    [Abstract] [Full Text] [Related]

  • 10. Suppressive effect of modified dominant negative RAS mutant on human cancer by gene transfer with non-viral vector.
    Suzuki H, Kuzumaki S, Nakagawa K, Takimoto M, Shichinohe T.
    Cancer Biol Ther; 2006 Nov 01; 5(11):1487-91. PubMed ID: 17102594
    [Abstract] [Full Text] [Related]

  • 11. Platelet-derived growth factor stimulation of mitogen-activated protein kinases and cyclin D1 promoter activity in cultured airway smooth-muscle cells. Role of Ras.
    Page K, Li J, Hershenson MB.
    Am J Respir Cell Mol Biol; 1999 Jun 01; 20(6):1294-302. PubMed ID: 10340949
    [Abstract] [Full Text] [Related]

  • 12. Stimulation of the P-450 side chain cleavage enzyme (CYP11A1) promoter through ras- and Ets-2-signaling pathways.
    Pestell RG, Albanese C, Watanabe G, Lee RJ, Lastowiecki P, Zon L, Ostrowski M, Jameson JL.
    Mol Endocrinol; 1996 Sep 01; 10(9):1084-94. PubMed ID: 8885243
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. MEK and ERK activation in ras-disabled RBL-2H3 mast cells and novel roles for geranylgeranylated and farnesylated proteins in Fc epsilonRI-mediated signaling.
    Graham TE, Pfeiffer JR, Lee RJ, Kusewitt DF, Martinez AM, Foutz T, Wilson BS, Oliver JM.
    J Immunol; 1998 Dec 15; 161(12):6733-44. PubMed ID: 9862703
    [Abstract] [Full Text] [Related]

  • 17. Growth factor-induced transcription via the serum response element is inhibited by cyclic adenosine 3',5'-monophosphate in MCF-7 breast cancer cells.
    Lowe WL, Fu R, Banko M.
    Endocrinology; 1997 Jun 15; 138(6):2219-26. PubMed ID: 9165004
    [Abstract] [Full Text] [Related]

  • 18. Requirement for Ras/Raf/ERK pathway in naringin-induced G1-cell-cycle arrest via p21WAF1 expression.
    Kim DI, Lee SJ, Lee SB, Park K, Kim WJ, Moon SK.
    Carcinogenesis; 2008 Sep 15; 29(9):1701-9. PubMed ID: 18296682
    [Abstract] [Full Text] [Related]

  • 19. Experimental gene therapy using p21Waf1 gene for esophageal squamous cell carcinoma by gene gun technology.
    Tanaka Y, Fujii T, Yamana H, Kato S, Morimatsu M, Shirouzu K.
    Int J Mol Med; 2004 Oct 15; 14(4):545-51. PubMed ID: 15375580
    [Abstract] [Full Text] [Related]

  • 20. Suppression of malignant growth potentials of v-Src-transformed human gallbladder epithelial cells by adenovirus-mediated dominant negative H-Ras.
    Tokumitsu Y, Nakano S, Ueno H, Niho Y.
    J Cell Physiol; 2000 May 15; 183(2):221-7. PubMed ID: 10737897
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 3.